IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy
about
Targeted drugs in small-cell lung cancerEfficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.Can we unlock the potential of IGF-1R inhibition in cancer therapy?The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.Research progress in the treatment of small cell lung cancer.Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination StudiesIGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination.Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition.Insulin-like growth factor-1 receptor regulates repair of ultraviolet B-induced DNA damage in human keratinocytes in vivo.IGF-1R expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer.IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).[Recent Advances and Future Strategies for Small Cell Lung Cancer].
P2860
Q26767017-16D9F9BA-5E1D-4496-A0EC-7367399F9F59Q30313117-7F7304CA-F204-4C32-A71B-62E99BD84E67Q34130987-95C04AAF-3754-4B75-9B1F-987AE8D4CB73Q34336988-38ACC172-520B-4B5A-BA69-0700831AFE92Q35609517-BB3312E0-CAFB-4829-9497-854638788F18Q35940305-697C0452-AFC2-46A3-80F7-23B087095334Q37604301-54CB9079-AB03-43D8-A3C1-F38456E341DCQ38641329-2534D75C-4A5F-41EA-901D-DD3E710E27AEQ38927010-09A470A4-7584-4235-9C95-8F238C790C6EQ38941146-85B92A72-F1C0-429E-90B1-443094EC6026Q41113979-BBD4A678-89DA-4912-BD37-8EF1881D9571Q41303851-AC672313-1139-4460-9A90-86F943087767Q42322249-7A6511B3-759C-4456-8ABB-1445D80EFA99Q42408770-A59EBEAA-A15F-479F-8332-774DB7799148Q51841208-49777A81-828D-4196-B5E9-9C31B110143D
P2860
IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
IGF-1R targeting increases the ...... e efficacy of standard therapy
@en
IGF-1R targeting increases the ...... efficacy of standard therapy.
@nl
type
label
IGF-1R targeting increases the ...... e efficacy of standard therapy
@en
IGF-1R targeting increases the ...... efficacy of standard therapy.
@nl
prefLabel
IGF-1R targeting increases the ...... e efficacy of standard therapy
@en
IGF-1R targeting increases the ...... efficacy of standard therapy.
@nl
P2093
P2860
P50
P1476
IGF-1R targeting increases the ...... e efficacy of standard therapy
@en
P2093
Andrea Gombos
Benoit Lahon
Charles Ferté
Frederic Commo
Julien Calderaro
Nathalie Auger
Saad Hamama
Yohann Loriot
P2860
P304
P356
10.1158/1535-7163.MCT-12-1067
P50
P577
2013-05-02T00:00:00Z